Related Experiment Video
Updated: Feb 14, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Martina Di Modica1, Elda Tagliabue1, Tiziana Triulzi1
1Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract:
HER2 is overexpressed in 20% of invasive breast cancers (BCs) and correlates with a more aggressive disease. Until the advent of targeted agents, HER2 was associated with worse outcomes. Rationally designed HER2-targeted agents have been developed and introduced into clinical practice for women with HER2-amplified BC, improving disease-free and overall survival for primary and metastatic tumors. Trastuzumab, a recombinant humanized anti-HER2 monoclonal antibody, combined with chemotherapy, remains the standard of care for patients with HER2-positive BCs. However, many patients do not respond to this agent, whereas newer drugs have proven to be efficacious in clinical trials. The identification of biomarkers that select sensitive tumors and patients who will benefit from these new agents would help the incorporation of these therapies, limiting the risk of side effects and overtreatment and improving the outcomes of all patients with early-stage HER2-positive BC. We review the mechanisms of action of HER2-targeting agents, focusing on the involvement of the immune system and related predictive biomarkers.
Insights
HER2-positive breast cancer treatments are improving survival, but not all patients respond. Identifying biomarkers can help select patients for newer HER2-targeted therapies, improving outcomes and reducing side effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- HER2 overexpression in 20% of breast cancers (BCs) indicates aggressive disease.
- HER2-targeted agents have improved survival in HER2-amplified BC.
- Trastuzumab is standard care but lacks efficacy in some patients.
Purpose of the Study:
- To review HER2-targeting agents' mechanisms of action.
- To focus on the immune system's role in HER2-targeted therapy.
- To identify predictive biomarkers for treatment selection.
Main Methods:
- Literature review of HER2-targeted agents.
- Analysis of immune system involvement in HER2-positive BC.
- Exploration of predictive biomarker strategies.
Main Results:
- HER2-targeted agents offer improved survival for HER2-amplified BC.
- Newer agents show efficacy beyond trastuzumab.
- Biomarkers are crucial for patient selection and treatment optimization.
Conclusions:
- Targeted therapies have transformed HER2-positive BC management.
- Understanding immune system interactions is key.
- Biomarker discovery will personalize treatment and improve outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Self-Efficacy
Predicting Molecular Geometry
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Gene Therapy
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

